No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...

Novo Nordisk's economic moat is eroding due to increased competition and US drug price pressures, but growth in international ...

U.S. pharma bounced back in Q2, and in this episode of "The Top Line," Fierce Pharma's Eric Sagonowsky and Kevin Dunleavy ...

As Novo Nordisk's sales of its blockbuster weight-loss drug Wegovy boomed, the Danish drugmaker raced to expand manufacturing ...

A week on from increases in the cost of Eli Lilly’s weight loss drug Mounjaro (tirzepatide), weight loss medication provider ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.

Viking Therapeutics stock sinks after mixed results from its obesity pill trial, raising doubts over safety, tolerability and ...

Novo Nordisk raced to meet demand for its weight-loss drug Wegovy and almost doubled its workforce over five years. Now, the ...

Drugmaker Novo Nordisk (NVO) will offer a reduced 2025 yearly bonus to its employees in Denmark due to the company’s lowered ...

What goes up must come down — here are the major drugs falling the hardest at the top companies so far this year.

Hyderabad-based Natco Pharma has filed a lawsuit against Danish drugmaker Novo Nordisk, the maker of blockbuster weight-loss ...

People with type 2 diabetes treated with GLP-1 receptor agonists may face a slightly higher risk for eye complications ...